Rosiglitazone Related Compound A (25 mg) ((5Z)-5-{[4-({2-[methyl(2-pyridinyl)amino]ethyl}oxy)phenyl]methylidene}-1,3-thiazolidine-2,4-dione)
![Rosiglitazone Related Compound A (25 mg) ((5Z)-5-{[4-({2-[methyl(2-pyridinyl)amino]ethyl}oxy)phenyl]methylidene}-1,3-thiazolidine-2,4-dione) price.](/CAS/20200515/GIF/160596-25-8.gif)
|
- $511 - $625
- Product name: Rosiglitazone Related Compound A (25 mg) ((5Z)-5-{[4-({2-[methyl(2-pyridinyl)amino]ethyl}oxy)phenyl]methylidene}-1,3-thiazolidine-2,4-dione)
- CAS: 160596-25-8
- MF: C18H17N3O3S
- MW: 355.41
- EINECS:928-889-9
- MDL Number:
- Synonyms:Rosiglitazone Related Compound A (25 mg) ((5Z)-5-{[4-({2-[methyl(2-pyridinyl)amino]ethyl}oxy)phenyl]methylidene}-1,3-thiazolidine-2,4-dione);Rosiglitazone Related CoMpound A;(5Z)-5-{[4-({2-[Methyl(2-pyridinyl)amino]ethyl}oxy)phenyl]methylidene}-1,3-thiazolidine-2,4-dione;2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methylene]-, (5Z)-;5Z-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methylene]-2,4-thiazolidinedione;Rosiglitazone Related Compound A ((5Z)-5-{[4-({2-[methyl(2-pyridinyl)amino]ethyl}oxy)phenyl]methyli (1605828);(5Z)-5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]-phenyl]methylene]-2,4-thiazolidinedione
2 prices
Selected condition：
Brand
- Sigma-Aldrich
- TRC
Package
- 25mg
- ManufacturerSigma-Aldrich
- Product number1605828
- Product descriptionRosiglitazone Related Compound A
- Packaging25mg
- Price$511
- Updated2024-03-01
- Buy
- ManufacturerTRC
- Product numberR693495
- Product description(5Z)-Rosiglitazone
- Packaging25mg
- Price$625
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Sigma-Aldrich | 1605828 | Rosiglitazone Related Compound A | 25mg | $511 | 2024-03-01 | Buy |
| TRC | R693495 | (5Z)-Rosiglitazone | 25mg | $625 | 2021-12-16 | Buy |
Properties
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|